🔗 Share this article

Given that the US continues making historic changes to its vaccination schedules, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by questioning COVID-19 vaccines during the global health crisis and has concentrated on potential deaths after COVID-19 immunization in her brief position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Schedule

Public health authorities planned to unveil sweeping changes to the pediatric immunization program in December, aligning the US with the Danish national calendar, sources say – a major change that would put the US at odds with much of the global community with insufficient data for improved outcomes. The announcement has been delayed until the next year.

Rather than Vinay Prasad, Høeg is scheduled to present at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth appointee to lead the division this year.

A Shift at the Regulatory Body

This interim role could signify a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Prasad solidify control at the FDA – and it signals a greater focus upon dismantling already-approved vaccines at the FDA.

Høeg has repeatedly called for discontinuing specific childhood vaccine recommendations in the US in order to be more like the Danish model, a nation with comprehensive healthcare and a population about the population of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Background

Dr. Høeg has little discernible background in medication creation, oversight or administrative roles, which has been customary for past leaders of the biologics center. She has been employed at the FDA as a senior adviser to the agency head and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the CDER, said Dr. Jonathan Howard. “She has not conducted a scientific study. She is not versed in leading a large organization. She is not an expert in pharmaceutical oversight.”

Previous heads of the center would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she has not acquired the type of experience that previous people who ran CBER have had.”

This division has an vast range of responsibilities at the agency, Woodcock pointed out.

“Many people just focuses on the new drug program, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and other areas, and every single one must be supervised,” Dr. Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a significant administrative element to the position, which manages more than 5,000 staff members. “It’s a huge administrative position, if you do it right,” she added.

Official Statement and Controversial Policies

In response to concerns about Høeg’s credentials and whether this assignment signifies increased cooperation among FDA leaders on immunizations, a press secretary responded that the “concerns rely on flawed premises”.

“Her experience matches the functions of her job,” the spokesperson explained, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial one-day therapy clearance system that reportedly worried her former heads. “By what process are these drugs being selected for this voucher program? Who makes the choices?” Dr. Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed rules of pharmaceuticals, aside from vaccines.”

Documented Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if troubling, past, Howard observe. She authored a analysis using non-validated volunteer-provided data to assess the frequency of heart inflammation following COVID-19 vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are more dangerous than they are.

Part of her “policy goals” for the incoming federal leadership featured altering guidelines for novel immunizations and ending “optional” immunizations, she remarked after the election on a podcast. At the agency, Dr. Høeg has reportedly proposed barring teenage boys from getting COVID-19 vaccinations.

“She is an all-around true believer who commences with her beliefs and tailors the evidence to retrofit the data in a highly deceptive, untruthful fashion,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|